Glioblastomas (GBMs) comprise >50% of all primary brain tumors and are the most malignant type, with a median survival of 14 months and 90% of patients dying within 5 years. Effective treatment is hindered by our limited understanding of disease progression as well as complications such as resistance to existing drugs. The goal of the Tannous lab is therefore to understand the mechanisms underlying GBM progression and therapeutic resistance and to develop novel diagnostics and therapeutics. Specifically, the group is developing ways to better target GBM stem cells, the subpopulation of GBM cells that is largely responsible for tumor resistance and recurrence; it is studying the signals that tumor cells can send to their surrounding to promote tumor expansion; and it is developing blood-based tests and biomarkers to detect brain tumors and monitor disease progression. The resulting technologies and therapies can also be extended to other cancer types, and the Tannous lab is exploring such applications in collaboration with other groups.